DySIS Medical Appoints Chairman
News Jan 07, 2014
Mr. Cascella was previously Chief Executive Officer and President of Hologic Inc., a leading manufacturer and supplier of diagnostic products, medical imaging systems, and surgical products for Women’s Healthcare, between 2003 and 2013. He has over 30 years of senior management, operational and finance experience. Prior to Hologic, Mr. Cascella served as Managing Partner of CFG Capital LLC, an investment banking firm specialising in healthcare and was the Chief Operating Officer and Vice President of Finance at NeoVision Corporation, a developer of 3D ultrasound technology used for real-time guidance of interventional breast procedures.
Alastair Atkinson, CEO of DySIS Medical, said: “We welcome Robert as Chairman. His industry knowledge, market and technology expertise and extensive connections in the Women’s Healthcare industry add substantial value to our team. I look forward to working with him to move DySIS into the next stage of growth and expansion.
“I look forward to working with Alastair and the team on the commercialisation strategy of a technology capable of significantly improving upon the diagnostic protocols for cervical disease,” Mr. Cascella added. “DySIS has the unique opportunity to increase the effectiveness of the current standard of care in developed markets, while potentially addressing an unmet healthcare need in emerging markets, where the diagnosis and treatment of cervical disease remains woefully inadequate.”
DySIS Medical, a medical devices company active within Women’s Health, has developed an advanced cervical scan which, in addition to performing traditional colposcopy examinations, uses dynamic spectral imaging to scan, quantify and map the cervix.
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Potential Barcode Identified for a Form of Alcoholic Liver DiseaseNews
NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018